Uncategorized

Ivantis Completes Enrollment in Pivotal HYDRUS IV Glaucoma Study of the Hydrus™ Microstent

by Business Wire • 2015/04/17 • 0 Comments

IRVINE, Calif.--(BUSINESS WIRE)--Ivantis Completes Enrollment in Pivotal HYDRUS IV Glaucoma Study of the Hydrus™ Microstent; Clinical Milestone is Major Step Forward to FDA Review of Innovative and Less Invasive Glaucoma Technology

Full Story →

← Exfoliation syndrome (XFS): Discovered gene allows a peek into the future on eye disease

Modernizing Medicine Showcases New Mobile EMA Ophthalmology EMR System at the American Society of Cataract & Refractive Surgery Annual Symposium 2015 →

Post navigation